Drug Information

General Information
Drug ID
DR00032
Drug Name
Imatinib
Synonyms
112GI019; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide; Alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI); CGP 57148B; Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib Methansulfonate; Imatinib [INN:BAN]; Imatinib free base; N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; STI; STI 571; STI571; Sti-571
Drug Type
Small molecular drug
Indication Gastrointestinal stromal tumor [ICD11: 2B5B] Approved [1]
Chronic myelogenous leukemia [ICD11: 2A20.0] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C29H31N7O
Canonical SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
InChI
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
InChIKey
KTUFNOKKBVMGRW-UHFFFAOYSA-N
CAS Number
CAS 152459-95-5
Pharmaceutical Properties Molecular Weight 493.6 Topological Polar Surface Area 86.3
Heavy Atom Count 37 Rotatable Bond Count 7
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 7
XLogP
3.5
PubChem CID
5291
PubChem SID
14859628 , 22394533 , 24424247 , 26697112 , 26737110 , 29215405 , 29215406 , 29224346 , 46392211 , 46393540 , 46505055 , 46507948 , 46513933 , 49655235 , 50066026 , 50070642 , 50100104 , 50109856 , 50353059 , 53788935 , 53799240 , 5619104 , 56311252 , 56311284 , 56311359 , 56311779 , 56311988 , 56312022 , 56312838 , 56313109 , 56313183 , 56313522 , 56313562 , 56314521 , 57288246 , 57288452 , 57288559 , 57288780 , 57322698 , 57551951 , 57578266 , 584799 , 7890613 , 7979593 , 8153249 , 822644 , 828861 , 832827 , 841977 , 85171056
ChEBI ID
ChEBI:45783
TTD Drug ID
D0AZ3C
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [3]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [4]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [4]
OCT-1 Transporter Info Organic cation transporter 1 Substrate [5]
P-GP Transporter Info P-glycoprotein 1 Substrate [6]
References
1 Imatinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
3 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
4 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
5 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
6 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.